167837-50-5

Basic information

• Product Name: 5-Quinoxalinol, 3-methyl-
• Synonyms: 5-Quinoxalinol, 3-methyl-;3-methyl-5-Quinoxalinol
• CAS NO: 167837-50-5
• Molecular Formula: C₉H₈N₂O
• Molecular Weight: 160.17
• Mol File: 167837-50-5.mol
• Article Data: 3

Chemical Properties

• Melting Point: 83-84 °C
• Boiling Point: 312.4±37.0 °C(Predicted)
• Appearance: /
• Density: 1.284±0.06 g/cm3(Predicted)
• PKA: 6.93±0.40(Predicted)
• CAS DataBase Reference: 5-Quinoxalinol, 3-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Quinoxalinol, 3-methyl-(167837-50-5)
• EPA Substance Registry System: 5-Quinoxalinol, 3-methyl-(167837-50-5)

Safety Data

• Hazardous Substances Data: 167837-50-5(Hazardous Substances Data)

Upstream product

• 59649-56-8 2,3-diaminophenol 
• 78-98-8 2-oxopropanal 
• 127-09-3 sodium acetate 

Downstream Products

• 179622-77-6 2-Amino-N-[2,4-dimethyl-3-(3-methyl-quinoxalin-5-yloxymethyl)-phenyl]-N-methyl-acetamide 
• 167837-88-9 8-[3-(N-Glycyl-N-methylamino)-2,6-dichlorobenzyloxy]-2-methylquinoxaline 
• 179623-82-6 8-[3-[N-[(E)-3-(6-Carboxypyridin-3-yl)acryloylglycyl]-N-methylamino]-2,6-dimethylbenzyloxy]-2-methylquinoxaline 
• 179623-54-2 8-[2,6-Dimethyl-3-[N-[(E)-3-(6-ethoxycarbonylpyridin-3-yl)acryloylglycyl]-N-methylamino]benzyloxy]-2-methylquinoxaline 
• 167834-56-2 8-(2,6-Dichloro-3-nitro-benzyloxy)-2-methyl-quinoline 
• 179626-11-0 8-[2,6-Dimethyl-3-[N-(phthalimidoacetyl)-N-methylamino]benzyloxy]-2-methylquinoxaline 

Relevant articles and documents

NEUROLOGICALLY-ACTIVE COMPOUNDS

The present invention relates to neurologically-active compounds, being heterocyclic compounds having two fused 6-membered rings with a nitrogen atom at position 1 and a hydroxy or mercapto group at position 8 with at least one ring being aromatic. Also disclosed are processes for the preparation of these compounds and their use as pharmaceutical or veterinary agents, in particular for the treatment of neurological conditions, more specifically neurodegenerative conditions such as Alzheimer's disease.

BRADYKININ ANTAGONIST QUINOLINES

This invention relates to new heterocyclic compounds and pharmaceutically acceptable salts thereof. More particularly, this invention relates to new heterocyclic compounds and salts thereof which display bradykinin antagonist activity, to processes for preparing these compounds, to a pharmaceutical composition comprising these compounds, and to methods of using same in the prevention and/or the treatment of bradykinin-or bradykinin analogue-mediated diseases such as allergy, inflammation, autoimmune disease, shock, pain, or the like, in human beings or in animals.